Suggested remit - To appraise the clinical and cost-effectiveness of nivolumab with ipilimumab within its marketing authorisation for adjuvant treatment of completely resected stage III or IV melanoma
Status In progress
Process STA 2018
ID number 1610

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
13 September 2019 - 11 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 August 2019 In progress, Referred 31 July 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance